Corient Private Wealth
NBIX icon

Corient Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Corient Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.91M Buy
45,035
+32,386
+256% +$4.3M 0.01% 788
2025
Q4 		$1.79M Buy
12,649
+8,644
+216% +$1.25M ﹤0.01% 1580
2025
Q3 		$562K Sell
4,005
-866
-18% -$117K ﹤0.01% 1732
2025
Q2 		$612K Buy
4,871
+671
+16% +$77K ﹤0.01% 1597
2025
Q1 		$465K Sell
4,200
-3,727
-47% -$472K ﹤0.01% 1635
2024
Q4 		$1.08M Buy
7,927
+3,094
+64% +$383K ﹤0.01% 1282
2024
Q3 		$557K Buy
4,833
+397
+9% +$54.4K ﹤0.01% 1676
2024
Q2 		$611K Buy
4,436
+617
+16% +$84.6K ﹤0.01% 1542
2024
Q1 		$527K Buy
3,819
+637
+20% +$87K ﹤0.01% 1603
2023
Q4 		$419K Buy
3,182
+23
+0.7% +$2.65K ﹤0.01% 1697
2023
Q3 		$355K Buy
3,159
+110
+4% +$11.6K ﹤0.01% 1662
2023
Q2 		$288K Sell
3,049
-2,145
-41% -$210K ﹤0.01% 1720
2023
Q1 		$526K Buy
+5,194
New +$540K ﹤0.01% 1360

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Private Wealth's NBIX Position: Q1 2026 in Review

Corient Private Wealth increased its Neurocrine Biosciences (NBIX) stake by 256% in Q1 2026, buying an estimated $4.3M and bringing the position to 45,035 shares worth $5.91M. The position accounts for 0.01% of the portfolio, ranked #788.

Corient Private Wealth first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Corient Private Wealth held 45,035 shares of Neurocrine Biosciences worth $5.91M as of Q1 2026.
  • Corient Private Wealth bought 32,386 Neurocrine Biosciences shares in Q1 2026, an estimated $4.3M.
  • Neurocrine Biosciences made up 0.01% of Corient Private Wealth's portfolio in Q1 2026, its #788 holding.
  • Corient Private Wealth first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.